Details

Autor(en) / Beteiligte

• Le, Thuy
• Kinh, Nguyen Van
• Cuc, Ngo T.K
• Tung, Nguyen L.N
• Lam, Nguyen T
• Thuy, Pham T.T
• Cuong, Do D
• Phuc, Pham T.H
• Vinh, Vu H
• Hanh, Doan T.H
• Tam, Vu Van
• Thanh, Nguyen T
• Thuy, Tran P
• Hang, Nguyen T
• Long, Hoang B
• Nhan, Ho T
• Wertheim, Heiman F.L
• Merson, Laura
• Shikuma, Cecilia
• Day, Jeremy N
• Chau, Nguyen V.V
• Farrar, Jeremy
• Thwaites, Guy
• Wolbers, Marcel

Titel

A Trial of Itraconazole or Amphotericin B for HIV-Associated Talaromycosis

Ist Teil von

• The New England journal of medicine, 2017-06, Vol.376 (24), p.2329-2340

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2017

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Talaromyces marneffei is a dimorphic fungus that causes substantial disease in Asia, especially among persons infected with the human immunodeficiency virus. In this randomized, controlled trial, initial therapy with amphotericin B was found to be superior to itraconazole. The dimorphic fungus Talaromyces (previously Penicillium ) marneffei causes a life-threatening mycosis in immunocompromised persons living in or traveling to Southeast Asia, China, and India. 1 Talaromycosis (previously penicilliosis) is a major cause of human immunodeficiency virus (HIV)–related death; its prevalence is surpassed only by the prevalence of tuberculosis and cryptococcosis, 2 and it leads to 4 to 15% of HIV-related hospital admissions in regions in which the disease is endemic. 3 – 7 Talaromycosis is increasingly diagnosed among patients who are not infected with HIV but who have other immunodeficiency conditions 8 and is reported to be the second most common cause of all . . .